GLP-1 oral transition and price cuts
The Trump administration is facilitating dramatic price reductions and oral formulations for GLP-1 medications to broaden access and curb long-term healthcare expenditure.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day — no card required.